Fullerol optimized matrigel as well as preparation method and application thereof

By using fullerol to optimize the matrix gel, the instability of small intestinal organoids during growth was solved, and their growth and development were promoted through antioxidant effects, thereby improving the structural and functional consistency of small intestinal organoids.

CN119020259APending Publication Date: 2024-11-26XIAMEN UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411119359.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing small intestinal organoids suffer from structural instability, incomplete differentiation, and batch-to-batch variability during growth, necessitating optimization of culture methods to improve their stability and functional consistency.

Method used

Fullerol was used to optimize the matrix gel. Fullerol [C60(OH)n, n=25-40], a C60 derivative of fullerene, was prepared and mixed with the matrix gel for the culture of small intestinal organoids. It served as an antioxidant to inhibit apoptosis and promote growth and development.

Benefits of technology

It enhances the vitality of small intestinal organoids, increases ATP content, significantly upregulates the expression of cell cycle-related genes, downregulates the expression of apoptosis genes, reduces ROS levels, decreases cell apoptosis, and promotes the growth and development of small intestinal organoids.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020259A_ABST
    Figure CN119020259A_ABST
Patent Text Reader

Abstract

The invention discloses fullerol optimized matrigel as well as a preparation method and application thereof. The preparation method comprises the following steps: preparing fullerol C60 (OH) n of which the hydroxyl substitution number n is equal to 25-40 through a TBAH catalytic alkaline method, and mixing the fullerol C60 (OH) n with culture matrigel to obtain the fullerol optimized matrigel. Fullerol is used as an antioxidant to enhance the activity of small intestine organoid, increase the ATP content and promote the growth and development of the organoid in the early stage, so that the matrigel can significantly up-regulate the gene expression related to the cell cycle, up-regulate the gene expression level of Bcl2 for inhibiting apoptosis and down-regulate the gene expression level of Caspase3 related to apoptosis generation; rOS (reactive oxygen species) of small intestine organs is remarkably reduced, and cell apoptosis is remarkably reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a fullerol-optimized matrix glue and a preparation method and application thereof. Background Art

[0002] Organoids refer to tissue analogs with a certain spatial structure formed by three-dimensional (3D) culture of adult stem cells or pluripotent stem cells in vitro. Organoids can simulate real organs in structure and function, can simulate the structure and function of in vivo tissues to the greatest extent, and can be cultured stably for a long time. Their culture requires matrix gel and culture medium containing specific organ growth factors. Small intestinal organoids are widely used in disease, drug research, and toxicology, but they are still different from real organs in the body. During the growth process of small intestinal organoids, there will be problems such as structural and morphological instability, incomplete differentiation and function, and batch-to-batch differences, so the culture method needs to be further optimized and standardized.

[0003] Fullerene is an allotrope of carbon, whose molecules are composed of carbon atoms and are spherical, ellipsoidal or tubular. The most famous fullerene is C60, whose molecular structure is similar to a soccer ball, consisting of 20 hexagons and 12 pentagons. Fullerol, also known as hydroxylated fullerene, is a derivative of fullerene (such as C60 or C70), which is formed by introducing multiple hydroxyl (-OH) groups on the fullerene molecule through a chemical reaction. By introducing hydroxyl groups, the water solubility of fullerol is significantly improved. Fullerol has excellent antioxidant properties, and its hydroxyl groups can effectively neutralize free radicals and prevent cell damage, and has potential antioxidant and anti-inflammatory effects. Summary of the invention

[0004] The purpose of the present invention is to overcome the shortcomings of the prior art, provide a fullerol optimized matrix glue and a preparation method and use thereof, and solve the problems in the above-mentioned background technology.

[0005] One of the technical solutions adopted by the present invention to solve its technical problem is: providing a fullerol-optimized matrix glue, which is a mixture of fullerol and matrix glue, wherein the content of fullerol is 0.1-10 μg / mL, the fullerol is a derivative of fullerene C60, and the number of introduced hydroxyl groups n=25-40.

[0006] The second technical solution adopted by the present invention to solve the technical problem is: providing a method for preparing fullerol-optimized matrix glue, comprising the following steps:

[0007] 1. Preparation of fullerene alcohol: add sodium hydroxide solution and TBAH aqueous solution to the toluene solution of fullerene C60, stir evenly, then add hydrogen peroxide, stir and react at 40°C for 4 hours; after removing the toluene phase, transfer the aqueous phase to a 3000 molecular weight dialysis bag, dialyze to remove small molecules in the aqueous phase; take out the aqueous solution in the dialysis bag, and remove the solvent water by rotary evaporation; add distilled water to dissolve, then add to ethanol until solid precipitates, filter, wash, and dry to obtain fullerene alcohol [C60(OH)n, n=25-40];

[0008] 2. Preparation of optimized matrix gel: The fullerol prepared in step 1 is mixed with the matrix gel to obtain an optimized matrix gel with a fullerol content of 0.1-10 μg / mL.

[0009] In a preferred embodiment of the present invention, in step 1, the usage ratio of fullerene C60 to toluene solution is 5 mg:3 mL.

[0010] In a preferred embodiment of the present invention, in step 1, fullerene C60 is dissolved in a toluene solution to obtain a toluene solution of fullerene C60, 30% sodium hydroxide solution and 25% TBAH aqueous solution are added to the toluene solution of fullerene C60, and after stirring evenly, 30% hydrogen peroxide is added for reaction, wherein the dosage ratio of fullerene C60, toluene solution, sodium hydroxide solution, TBAH aqueous solution, and hydrogen peroxide is 500 mg: 300 mL: 10 mL: 5 mL: 70 mL.

[0011] In a preferred embodiment of the present invention, in step 1, the aqueous phase is transferred to a dialysis bag with a molecular weight of 3000, and the small molecules of NaOH, TBAH, and H2O2 in the aqueous phase are dialyzed to remove the conductivity of pure water outside the dialysis bag to 10 μS / cm.

[0012] In a preferred embodiment of the present invention, in step 1, the aqueous solution in the dialysis bag is taken out, and the solvent water is removed by rotary evaporation; then 5 mL of distilled water is added to dissolve, and then added to 50 mL of ethanol until a solid precipitates, and filtered to obtain a khaki solid, which is washed with ethanol three times and dried to obtain fullerene alcohol [C60(OH)n, n=25-40].

[0013] The third technical solution adopted by the present invention to solve its technical problem is: providing a use of fullerol-optimized matrix gel, mixing fullerol [C60(OH)n, n=25-40] with matrix gel to obtain fullerol-optimized matrix gel for culturing small intestinal organoids.

[0014] In a preferred embodiment of the present invention, fullerenol-optimized matrix gel is used as an antioxidant to inhibit cell apoptosis and promote the growth and development of small intestinal organoids in the early stage.

[0015] In a preferred embodiment of the present invention, the following steps are included:

[0016] (I) Isolation of small intestinal stem cells: small intestinal crypt cells are obtained by cutting and dissociating a section of small intestine;

[0017] (ii) Small intestinal organoid culture: Small intestinal crypt cells were mixed with fullerene-optimized matrix gel, seeded on a cell culture plate, and small intestinal organoid complete culture medium was added externally until small intestinal organoids were formed.

[0018] In a preferred embodiment of the present invention, step (ii) comprises: resuspending the obtained small intestinal crypt cells in fullerol-optimized matrix gel at a density of 70-100 crypts per 10 μL fullerol-optimized matrix gel, inoculating in a cell culture plate, and inverting the inoculated culture plate at 37°C for 25 minutes; using a pipette to add small intestinal organoid complete culture medium to each well along the side wall of the well, covering the lid of the culture plate, and culturing at 37°C and 5% CO2, and replacing the culture medium every 3 days.

[0019] Compared with the background technology, this technical solution has the following advantages:

[0020] 1. The fullerol in the matrix gel optimized in this protocol can be used as an antioxidant to enhance the vitality of small intestinal organoids, increase ATP content, and promote the growth and development of organoids in the early stages;

[0021] 2. The optimized matrix gel in this scheme can significantly upregulate the expression of genes related to the cell cycle, upregulate the gene expression level of Bcl2 that inhibits apoptosis, and downregulate the gene expression level of Caspase3 related to apoptosis;

[0022] 3. The optimized matrix gel in this scheme can significantly reduce ROS in small intestinal organoids and significantly reduce cell apoptosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is the characterization of fullerol and the antioxidant capacity test results:

[0024] A. Electron microscopic results of fullerol; B. Particle size distribution of fullerol; C. Zeta potential of fullerol in DMEM culture medium and ddH2O; D. Infrared absorption spectrum of fullerol; E. DPPH detection of antioxidant capacity of fullerol; F. ABTS detection of antioxidant capacity of fullerol; G. Safety of fullerol detected in Beas-2B cells and FHs-74 cells. Significance is as follows: *: P<0.05.

[0025] Figure 2 This is the bright field photography and diameter statistics of small intestinal organoids at different stages after fullerene-optimized matrix gel culture:

[0026] A. Schematic diagram of small intestinal organoid construction and fullerol treatment; B. Bright field photography of small intestinal organoids at different stages after fullerol treatment; C. Statistics of small intestinal organoid diameters at different stages after fullerol treatment. The significance is as follows: *: P < 0.05, **: P < 0.01.

[0027] Figure 3 This is the MTT, ATP content and immunofluorescence results of small intestinal organoids after fullerene-optimized matrix gel culture:

[0028] A. MTT assay for organoid viability after fullerol treatment; B. ATG assay for organoid ATP content after fullerol treatment; C. Immunofluorescence assay for Ki67, Muc2, ZO-1, and SOX9 expression after fullerol treatment. The significance is as follows: *: P<0.05, **: P<0.01.

[0029] Figure 4-7 This is the sequencing result of small intestinal organoids cultured on the fifth day in fullerene-optimized matrix gel.

[0030] A. Volcano plot of sequencing results of small intestinal organoids treated with fullerol on the fifth day; B. Heat map of sequencing results of small intestinal organoids treated with fullerol on the fifth day; C. GO enrichment analysis results of small intestinal organoids treated with fullerol on the fifth day; D. KEGG enrichment analysis results of small intestinal organoids treated with fullerol on the fifth day; EH. GSEA enrichment results; I. Cell cycle-related gene detection; J. Apoptosis-related gene detection. The significance is as follows: *: P<0.05, **: P<0.01.

[0031] Figure 8 This is the result of fullerol-optimized matrix gel reducing ROS levels in small intestinal organoids.

[0032] A. ROS levels of small intestinal organoids treated with fullerol at different time points (detection results by microplate reader); B. ROS staining of small intestinal organoids treated with fullerol at different time points (DCFH-DA fluorescence photography results); C. Quantitative detection results of ROS staining fluorescence intensity. The significance is as follows: *: P < 0.05, **: P < 0.01.

[0033] Fig. 9 This is the result of fullerol-optimized matrix gel inhibiting apoptosis of small intestinal organoids.

[0034] A. Calcein-AM / PI staining of small intestinal organoids treated with fullerol at different time points; B. Quantitative detection results of PI staining fluorescence intensity. The significance is as follows: *: P < 0.05. DETAILED DESCRIPTION

[0035] The present application is further described in detail below in conjunction with the accompanying drawings and examples. The reagents in the following examples are all commercially available unless otherwise specified, and the expression of % refers to the mass fraction unless otherwise specified. For example, "30% sodium hydroxide" refers to a sodium hydroxide solution with a mass fraction of 30%.

[0036] Example

[0037] A method for preparing fullerol-optimized matrix glue comprises the following steps:

[0038] 1. Preparation of fullerene alcohol:

[0039] Dissolve 500 mg of fullerene C60 in 300 ml of toluene solution and set aside;

[0040] Add 10 ml of 30% sodium hydroxide solution and 5 ml of 25% TBAH aqueous solution to the toluene solution of fullerene C60, stir evenly, then add 70 ml of 30% hydrogen peroxide, stir and react at 40°C for 4 hours, at which time the toluene phase changes from purple to colorless, and the aqueous phase turns from yellow to brown;

[0041] Use a separatory funnel to remove the toluene phase and retain the aqueous phase;

[0042] The water phase was transferred to a 3000 molecular weight dialysis bag, and the small molecules of NaOH, TBAH, and H2O2 in the water phase were removed by dialysis until the conductivity of pure water outside the dialysis bag was 10 μS / cm, indicating complete dialysis;

[0043] The aqueous solution in the dialysis bag was taken out and the solvent water was removed by rotary evaporation; 5 ml of distilled water was added to dissolve it, and then added to 50 ml of ethanol. A large amount of solid was precipitated, and a yellowish brown solid was obtained by filtration. Ethanol was added to wash 3 times, and the solid was dried to obtain fullerene alcohol [C60(OH)n, n=25-40].

[0044] 2. Preparation of optimized matrix gel: Mixing nano-fullerol with matrix gel to obtain optimized matrix gel, specifically:

[0045] Fullerol aqueous solutions of different concentrations were mixed with commercially available matrix gel at a ratio of 1:9 to obtain optimized matrix gel containing 0.1, 1, and 10 μg / mL fullerol, wherein the fullerol is a derivative of fullerene C60, and the number of introduced hydroxyl groups n=25-40.

[0046] It is used to culture small intestinal organoids. The specific steps are as follows:

[0047] 3. Isolation of small intestinal stem cells: Small intestinal crypt cells are obtained by cutting and dissociating a section of small intestine, specifically:

[0048] The intestinal tissue of 3 to 10 cm near the stomach end was selected from the killed mice, the mesentery and fat were removed, the villi on the surface of the intestinal cavity were scraped off and cut into pieces of 2 mm wide, and digested with digestive fluid (4℃30min), and the digestion was terminated when intact crypt cells were found under microscopic examination;

[0049] After washing and resuspending the cells, filter through a 70 μm filter, collect the tissue suspension passing through the filter, centrifuge (300 g at 4°C for 3 min), resuspend and count the cells.

[0050] 4. Cultivate small intestinal organoids in optimized matrix gel: Mix small intestinal crypt cells in matrix gel according to proportion, plant them in cell culture plates, and add small intestinal organoid complete culture medium externally until small intestinal organoids are formed. Specifically:

[0051] Resuspend the tissue pellet with an appropriate amount of optimized matrix gel to a density of 70-100 crypts per 10 μL matrix gel, inoculate it in a cell culture plate, and incubate the inoculated culture plate inverted at 37°C for 25 min;

[0052] Use a pipette to add small intestinal organoid complete culture medium to each well along the side wall of the well, cover the culture plate, and culture at 37°C and 5% CO2. Change the culture medium every 3 days.

[0053] The fullerol and its optimized matrix gel in this example were tested for their ability:

[0054] (I) Characterization and in vitro antioxidant capacity of fullerol

[0055] like Figure 1 As shown in AD, electron microscopy and particle size statistics show that the size of fullerol is about 200nm, and the Zeta potential in DMEM and ddH2O is negative. Through infrared spectroscopy scanning, typical -OH, CC, and CO bond peaks can also be observed.

[0056] The free radical scavenging and overall antioxidant capacity of fullerol were tested by DPPH and ABTS, respectively. The results showed that fullerol had good free radical scavenging ability, and its overall antioxidant capacity tended to increase with the dose. Figure 1 EF. Figure 1 As shown in G, at the cellular level, Beas-2B and FHs-74 cell tests found that fullerol did not cause a significant decrease in cell viability until the concentration was 100 μg / mL, which showed high safety. (II) Effect of fullerol on the growth of small intestinal organoids

[0057] Crypts were isolated from the small intestine of 6-8 week old C57 mice to construct small intestinal organoids. Fullerol-optimized matrix gel (made by mixing different concentrations of fullerol aqueous solution into the matrix gel for organoid culture) with fullerol contents of 0.1, 1, and 10 μg / mL was used. Figure 2 As shown in A. During the culture process, the small intestinal organoids were photographed and their sizes were counted. Figure 2 BC showed that fullerol-optimized matrix gel can significantly promote the increase of organoid size, suggesting that it has the effect of promoting organoid growth. The significance is as follows: *: P < 0.05, **: P < 0.01.

[0058] MTT and ATP were further used to detect the changes in organoid viability and mitochondrial energy after fullerol treatment. Figure 3 The AB results also showed that fullerol can significantly promote the growth and development of organoids in the early stage, and immunofluorescence detection of proteins related to the development of small intestinal organoids, such as Ki67, Muc2 and SOX9, showed an upward trend after fullerol treatment. Figure 3 C.

[0059] (III) Mechanism of fullerene promoting the growth of small intestinal organoids

[0060] like Figure 4 AB, Figure 5 As shown in CD, samples of small intestinal organoids treated with fullerol on the fifth day were selected for RNA-seq sequencing, and GO enrichment analysis found that cell cycle, oxidative phosphorylation, apoptosis and Wnt signaling pathways were enriched. Figure 6 EF, Figure 7 GH results showed that GSEA verification found that G2M checkpoint and Wnt signaling pathway had an upward trend, while ROSpathway and Apoptosis had a downward trend. Further examination of the expression of G2M checkpoint and Apoptosis-related genes revealed that the expression of genes related to the cell cycle was significantly upregulated, the gene expression level of Bcl2, which inhibits apoptosis, was increased, and the gene expression level of Caspase3, which is related to apoptosis, was significantly decreased, indicating that apoptosis was weakened. The results are shown in Figure 6 I. Figure 7 J. further verified the sequencing results.

[0061] like Figure 8 As shown in AC, the ROS level in organoids was detected using the DCFH-DA reactive oxygen species probe. We found that after fullerol treatment, the ROS level in organoids decreased significantly, which was consistent with the inhibition of ROS pathway in the sequencing results.

[0062] Apoptosis-related indicators were further tested, and the results are shown in Fig. 9 AB. Calcein-AM / PI fluorescent probe was used to detect the cell survival and death levels in organoids. It was found that after treatment, the PI fluorescence intensity in the organoids decreased significantly, indicating a decrease in the level of cell apoptosis, which was consistent with the inhibition of apoptosis levels in the sequencing results and q-PCR detection results.

[0063] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that the technical solutions described in the aforementioned embodiments may still be modified, or some or all of the technical features thereof may be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A fullerol-optimized matrix gel, Features: It is a mixture of fullerol and matrix gel, wherein the content of fullerol is 0.1-10 μg / mL, the fullerol is a derivative of fullerene C60, and the number of introduced hydroxyl groups n=25-40.

2. A method for preparing a fullerol-optimized matrix gel, Features: The steps include:

1. Preparation of fullerene alcohol: add sodium hydroxide solution and TBAH aqueous solution to the toluene solution of fullerene C60, stir evenly, then add hydrogen peroxide, stir and react at 40°C for 4 hours; after removing the toluene phase, transfer the aqueous phase to a 3000 molecular weight dialysis bag, dialyze to remove small molecules in the aqueous phase; take out the aqueous solution in the dialysis bag, and remove the solvent water by rotary evaporation; add distilled water to dissolve, then add to ethanol until solid precipitates, filter, wash, and dry to obtain fullerene alcohol [C60(OH)n, n=25-40]; 2. Preparation of optimized matrix gel: Mix the fullerol prepared in step 1 with the matrix gel to obtain an optimized matrix gel with a fullerol content of 0.1-10 μg / mL.

3. A method for preparing a fullerol-optimized matrix gel according to claim 2, Features: In step 1, the usage ratio of fullerene C60 to toluene solution is 5 mg:3 mL.

4. A method for preparing a fullerol-optimized matrix gel according to claim 2, Features: In step 1, fullerene C60 is dissolved in a toluene solution to obtain a toluene solution of fullerene C60, 30% sodium hydroxide solution and 25% TBAH aqueous solution are added to the toluene solution of fullerene C60, and after stirring evenly, 30% hydrogen peroxide is added for reaction, wherein the dosage ratio of fullerene C60, toluene solution, sodium hydroxide solution, TBAH aqueous solution, and hydrogen peroxide is 500 mg: 300 mL: 10 mL: 5 mL: 70 mL.

5. A method for preparing a fullerol-optimized matrix gel according to claim 2, Features: In step 1, the aqueous phase was transferred to a 3000 molecular weight dialysis bag to remove small molecules of NaOH, TBAH, and H 2 O 2 , until the conductivity of pure water outside the dialysis bag is 10μS / cm.

6. The method for preparing a fullerol-optimized matrix gel according to claim 2, Features: In step 1, the aqueous solution in the dialysis bag is taken out, and the solvent water is removed by rotary evaporation; 5 mL of distilled water is added to dissolve, and then added to 50 mL of ethanol until a solid precipitates, and a yellowish brown solid is obtained by filtration, and ethanol is added to wash 3 times, and then dried to obtain fullerene alcohol [C60(OH)n, n=25-40].

7. A use of fullerol-optimized matrix glue, Features: Fullerol [C60(OH)n, n=25-40] was mixed with Matrigel to obtain fullerol-optimized Matrigel for the culture of small intestinal organoids.

8. The use of a fullerol-optimized matrix glue according to claim 7, Features: Fullerene-optimized matrix gel was used as an antioxidant to inhibit cell apoptosis and promote the early growth and development of small intestinal organoids.

9. The use of a fullerol-optimized matrix glue according to claim 7, Features: The steps include: (I) Isolation of small intestinal stem cells: small intestinal crypt cells are obtained by cutting and dissociating a section of small intestine; (ii) Small intestinal organoid culture: Small intestinal crypt cells were mixed with fullerol-optimized matrix gel, seeded on a cell culture plate, and small intestinal organoid complete culture medium was added externally until small intestinal organoids were formed.

10. The use of a fullerol-optimized matrix gel according to claim 8, Features: Step (ii) comprises: resuspending the obtained small intestinal crypt cells in fullerol-optimized matrix gel at a density of 70-100 crypts per 10 μL fullerol-optimized matrix gel, inoculating the cells in a cell culture plate, inverting the inoculated culture plate and standing it at 37°C for 25 min; adding small intestinal organoid complete culture medium to each well along the side wall of the well using a pipette, covering the lid of the culture plate, and incubating the culture plate at 37°C and 5% CO 2 The culture medium was replaced every 3 days.